Literature DB >> 9591970

Scoliosis in patients treated with growth hormone.

E D Wang1, D S Drummond, J P Dormans, T Moshang, R S Davidson, D Gruccio.   

Abstract

Two hundred fifty children being treated with growth hormone were screened for scoliosis by using the Adams and Bunnell techniques. If indicated, an anteroposterior radiograph was done and measured by the Cobb and Risser methods. Scoliosis was defined as a frontal curve of > or = 10 degrees; progression, as a sustained increase of > or = 5 degrees, and a progressive curve as one > or = 25 degrees and meeting our criteria for orthotic management. In 10 of the 250 patients, scoliosis developed. Six curves were double major thoracic and lumbar; three thoraco-lumbar; and one single thoracic. Six of the 10 patients had progressive curves and required an orthosis. Their average annualized rate of progression was 26 degrees. Progression was associated with double major curves and an earlier Risser stage. Despite bracing, progression continued to fusion in three patients. We conclude that growth hormone may increase the risk of progression of scoliosis. Furthermore, the progression is frequently rapid and requires special vigilance by the treating physician.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9591970

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  16 in total

1.  Decreased osteogenic differentiation of mesenchymal stem cells and reduced bone mineral density in patients with adolescent idiopathic scoliosis.

Authors:  Weon Wook Park; Kuen Tak Suh; Jeung Il Kim; Seong-Jang Kim; Jung Sub Lee
Journal:  Eur Spine J       Date:  2009-08-12       Impact factor: 3.134

2.  Polymorphism in vitamin D receptor is associated with bone mineral density in patients with adolescent idiopathic scoliosis.

Authors:  Kuen Tak Suh; Il-Soo Eun; Jung Sub Lee
Journal:  Eur Spine J       Date:  2010-04-02       Impact factor: 3.134

3.  Growth patterns and the use of growth hormone in the mucopolysaccharidoses.

Authors:  L E Polgreen; B S Miller
Journal:  J Pediatr Rehabil Med       Date:  2010

4.  Adolescent idiopathic scoliosis and osteopenia).

Authors:  Mariana Chiru
Journal:  Maedica (Buchar)       Date:  2011-01

5.  Association between osteoprotegerin gene polymorphism and bone mineral density in patients with adolescent idiopathic scoliosis.

Authors:  Il-Soo Eun; Weon Wook Park; Kuen Tak Suh; Jeung Il Kim; Jung Sub Lee
Journal:  Eur Spine J       Date:  2009-08-25       Impact factor: 3.134

6.  Pathogenesis of adolescent idiopathic scoliosis in girls - a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy.

Authors:  R Geoffrey Burwell; Ranjit K Aujla; Michael P Grevitt; Peter H Dangerfield; Alan Moulton; Tabitha L Randell; Susan I Anderson
Journal:  Scoliosis       Date:  2009-10-31

7.  Rapid progression of scoliosis curve in a mature patient with undiagnosed pituitary macroadenoma: A rare case report.

Authors:  Weng Hong Chung; Chee Kidd Chiu; Chris Yin Wei Chan; Mun Keong Kwan
Journal:  Acta Orthop Traumatol Turc       Date:  2020-09       Impact factor: 1.511

8.  Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosis.

Authors:  Kuen Tak Suh; Sang-Sup Lee; Sang Hyun Hwang; Seong-Jang Kim; Jung Sub Lee
Journal:  Eur Spine J       Date:  2007-05-23       Impact factor: 3.134

Review 9.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation.

Authors:  L E Polgreen; M Plog; J D Schwender; J Tolar; W Thomas; P J Orchard; B S Miller; A Petryk
Journal:  Bone Marrow Transplant       Date:  2009-03-02       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.